TY - JOUR
T1 - Lack of tolerance development with long-term administration of PEGylated cholecystokinin
AU - Verbaeys, Isabelle
AU - León-Tamariz, Fabián
AU - Buyse, Johan
AU - Decuypere, Eddy
AU - Pottel, Hans
AU - Cokelaere, Marnix
PY - 2009/4
Y1 - 2009/4
N2 - Cholecystokinin (CCK) is a short acting satiating peptide hormone produced in the proximal small intestine. Daily CCK injection in rats initially inhibits food intake, but after several days, food intake is no longer affected, suggesting development of tolerance. Previously, we covalently coupled CCK to a 10 kDa polyethylene glycol (mPEG-OH) and showed that this conjugate, PEG-CCK9, produced a significantly longer anorectic effect than unmodified CCK9. The present study examined whether tolerance to the anorectic effect develops during long-term administration of PEG-CCK9. For 14 consecutive days, male Wistar rats (n = 12) received a daily i.p injection of 8 μg kg−1 of PEG-CCK9 and a control group received a daily control injection of mPEG-OH. Body weight and food intake were monitored daily during the experiment. Effects on the pancreas were investigated. On each day, injection of PEG-CCK9 induced an anorectic effect lasting 3–6 h, but failed to significantly reduce daily total food intake compared to controls. The body weight gain of the PEG-CCK9-treated animals was not different from controls. The PEG-CCK9-treated group had a significantly higher pancreas weight, mainly due to hyperplasia. In conclusion, PEG-CCK9 continued to have a daily suppressive effect on food intake when administered for 14 consecutive days, showing there was no development of tolerance.
AB - Cholecystokinin (CCK) is a short acting satiating peptide hormone produced in the proximal small intestine. Daily CCK injection in rats initially inhibits food intake, but after several days, food intake is no longer affected, suggesting development of tolerance. Previously, we covalently coupled CCK to a 10 kDa polyethylene glycol (mPEG-OH) and showed that this conjugate, PEG-CCK9, produced a significantly longer anorectic effect than unmodified CCK9. The present study examined whether tolerance to the anorectic effect develops during long-term administration of PEG-CCK9. For 14 consecutive days, male Wistar rats (n = 12) received a daily i.p injection of 8 μg kg−1 of PEG-CCK9 and a control group received a daily control injection of mPEG-OH. Body weight and food intake were monitored daily during the experiment. Effects on the pancreas were investigated. On each day, injection of PEG-CCK9 induced an anorectic effect lasting 3–6 h, but failed to significantly reduce daily total food intake compared to controls. The body weight gain of the PEG-CCK9-treated animals was not different from controls. The PEG-CCK9-treated group had a significantly higher pancreas weight, mainly due to hyperplasia. In conclusion, PEG-CCK9 continued to have a daily suppressive effect on food intake when administered for 14 consecutive days, showing there was no development of tolerance.
KW - Cholecystokinin
KW - Long-term administration
KW - Pancreas proliferation
KW - PEGylated Cholecystokinin
KW - Satiety
KW - Tolerance
UR - https://www.scopus.com/pages/publications/62749197307
U2 - 10.1016/j.peptides.2008.11.010
DO - 10.1016/j.peptides.2008.11.010
M3 - Artículo
C2 - 19084041
AN - SCOPUS:62749197307
SN - 0196-9781
VL - 30
SP - 699
EP - 704
JO - Peptides
JF - Peptides
IS - 4
ER -